Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.3K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

854
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
854
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

739
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
739
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

694
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
694

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor Expression of Cerebellar Degeneration-Related Protein 2-Like in Rapidly Progressive Cerebellar Syndrome Associated With Oropharyngeal Squamous Cell Carcinoma.

Cerebellum (London, England)·2026
Same author

Neuropathological and Molecular Features Associated With a Heterozygous DNAJC7 Mutation in Amyotrophic Lateral Sclerosis.

Neuropathology and applied neurobiology·2026
Same author

Autoimmune maladies of the brainstem.

Handbook of clinical neurology·2026
Same author

Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Rehabilitation challenges and progress in a patient with sensory ataxic Guillain-Barré syndrome: a case report.

Physiotherapy theory and practice·2026
Same author

The activation of classical and/or lectin complement pathway for the pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy.

Journal of neuroimmunology·2025

Related Experiment Video

Updated: Apr 22, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

9.9K

[C5: eculizumab].

Katsuichi Miyamoto1

  • 1Department of Neurology, Kinki University School of Medicine.

Brain and Nerve = Shinkei Kenkyu No Shinpo
|October 10, 2014
PubMed
Summary

Eculizumab, a monoclonal antibody, blocks complement system activation by targeting C5. It is approved for paroxysmal nocturnal hemoglobinuria and shows promise for treating complement-mediated neurological disorders.

Area of Science:

  • Immunology
  • Pharmacology
  • Neurology

Context:

  • The complement system is a critical part of innate immunity.
  • Complement system dysregulation is implicated in various autoimmune and neurological diseases.
  • Eculizumab targets the terminal complement cascade.

Purpose:

  • To review the mechanism of action of eculizumab.
  • To discuss the clinical applications of eculizumab in paroxysmal nocturnal hemoglobinuria.
  • To explore the potential of eculizumab in treating neurological disorders mediated by the complement system.

Summary:

  • Eculizumab is a humanized monoclonal antibody that inhibits the terminal complement cascade by binding to C5.
  • It prevents the formation of C5a and C5b, thereby blocking complement-mediated cell lysis.

More Related Videos

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method
14:48

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method

Published on: July 6, 2012

45.4K
Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

9.5K

Related Experiment Videos

Last Updated: Apr 22, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

9.9K
Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method
14:48

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method

Published on: July 6, 2012

45.4K
Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

9.5K
  • Eculizumab is clinically approved for paroxysmal nocturnal hemoglobinuria and is under investigation for neuromyelitis optica and myasthenia gravis.

    • Impact:

    • Eculizumab offers a targeted therapeutic approach for complement-mediated diseases.
    • Its efficacy in paroxysmal nocturnal hemoglobinuria demonstrates the potential of complement inhibition.
    • Further research may establish eculizumab as a treatment for intractable neurological conditions.